Annual revenue went from KRW 22.7 billion in 2022 to KRW 21.6 billion in 2023 (down 4.7% year on year), then KRW 38.4 billion in 2024 (up 77.6%) and KRW 81.3 billion in 2025 (up 112.0%). After the 2023 low, revenue rose two years in a row from 2024 through 2025, and 2025 was the largest year of 2022–2025.
Operating losses were KRW 2.05 billion in 2022, KRW 3.86 billion in 2023, KRW 3.2 billion in 2024 and KRW 7.24 billion in 2025, a loss every year from 2022 through 2025. Operating margin was -9.0%, -17.9%, -8.3% and -8.9%, so the 2025 margin was slightly worse than 2024 even though revenue more than doubled.
Net loss attributable to controlling shareholders was KRW 4.1 billion in 2022 and KRW 7.3 billion in 2023, turned to a KRW 197 million profit in 2024, and returned to a KRW 8.79 billion loss in 2025. Net income including non-controlling interests, a different figure, was a loss of KRW 12.4 billion in 2025.
The debt ratio rose from 14.1% in 2022 to 76.2% in 2025; at end-2025 total liabilities were KRW 108.1 billion and total equity KRW 141.8 billion, of which KRW 69.9 billion belonged to controlling shareholders.
Operating cash flow was negative in each of 2023 (-KRW 49.57 million), 2024 (-KRW 3.83 billion) and 2025 (-KRW 2.5 billion), after KRW 448 million in 2022.
Quarterly, Q3 2025 revenue was KRW 30 billion with an operating loss of KRW 248 million, and Q4 2025 revenue rose to KRW 31.1 billion with a KRW 1.07 billion operating loss.
Q1 2026 revenue was KRW 30.4 billion with KRW 502 million operating profit, Q2 2026 revenue was KRW 27.6 billion with KRW 279 million, down 44.4% from the prior quarter, and Q3 2026 revenue was KRW 40.7 billion, up 35.7% year on year, with KRW 1.67 billion operating profit.
In its first-half 2026 release, the company said cost of sales fell from 89% to 84% of revenue and SG&A from 40% to 15%. Part of 2026 growth also reflects consolidation of Techlabs in June and JK Medi in July.
Attributable net results ran a KRW 242 million profit in Q3 2025, then losses of KRW 2.95 billion in Q4 2025, KRW 965 million in Q1 2026 and KRW 2.23 billion in Q2 2026, before a KRW 367 million profit in Q3 2026; the last four quarters total a KRW 5.77 billion attributable net loss.